Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis

Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated w...

Full description

Saved in:
Bibliographic Details
Published in:Internal and emergency medicine 2024-08
Main Authors: Miró, Òscar, Mojarro, Enrique Martín, Huré, Gabrielle, Llorens, Pere, Gil, Víctor, Alquézar-Arbé, Aitor, Bibiano, Carlos, González, Nayra Cabrera, Massó, Marta, Strebel, Ivo, Espinosa, Begoña, Masó, Silvia Mínguez, Wussler, Desiree, Shrestha, Samyut, Lopez-Ayala, Pedro, Jacob, Javier, Millán, Javier, Andueza, Juan Antonio, Alonso, Héctor, Pàmies, Silvia Larrondo, Cerdà, Jaume Farré, Martínez, Celia Planco, Herrero, Pablo, Frank Peacock, W, Mueller, Christian
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title Internal and emergency medicine
container_volume
creator Miró, Òscar
Mojarro, Enrique Martín
Huré, Gabrielle
Llorens, Pere
Gil, Víctor
Alquézar-Arbé, Aitor
Bibiano, Carlos
González, Nayra Cabrera
Massó, Marta
Strebel, Ivo
Espinosa, Begoña
Masó, Silvia Mínguez
Wussler, Desiree
Shrestha, Samyut
Lopez-Ayala, Pedro
Jacob, Javier
Millán, Javier
Andueza, Juan Antonio
Alonso, Héctor
Pàmies, Silvia Larrondo
Cerdà, Jaume Farré
Martínez, Celia Planco
Herrero, Pablo
Frank Peacock, W
Mueller, Christian
description Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated with improved outcomes. We investigated factors related to digoxin initiation after an episode of AHF and whether patients receiving digoxin presented better short-term outcomes. We analyzed digoxin-naïve AHF patients from a Spanish and Swiss database, who were dichotomized into cohorts based on their receipt of digoxin treatment at discharge. The relationship between digoxin initiation and 23 additional patient covariates, including chronic treatment, was investigated, as well as its association with 90-day combined adverse events (defined as all-cause death or AHF hospitalization). Of 13,105 patients (10,600/2505 from the Spanish/Swiss cohorts, respectively), the median (interquartile range) age was 83 (74.87) years, and 51% were women. Of these, 484 (3.7%) received digoxin at discharge, which was associated with AF, female sex, left ventricular ejection fraction (LVEF) 
doi_str_mv 10.1007/s11739-024-03744-y
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_3096280174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3096280174</sourcerecordid><originalsourceid>FETCH-LOGICAL-p118t-a0420c06d6e818aa5115adc5f734f0d9e30bfea22b86d07fcb6c75fc6b22352f3</originalsourceid><addsrcrecordid>eNpNjstOwzAQRS0EEqXwA6y8ZBMY24mdsEPlKVViA-tq4oxbozQOsSPgK_hlAu2C1T3SzJy5jJ0LuBQA5ioKYVSVgcwzUCbPs68DNhOVgaxSWh_-42N2EuMbQFFoYWbs-9avw6fvuO988ph86Di6RAPHCeyYiG8Ih8Qd-nYciFPvY2hoGjfcp8gxxmD3hx8-bXgfYsoaH-0GhzXxMCYbthSvf4W-m8zd3zK2fDu2yVvqdt-w_Yo-nrIjh22ks33O2ev93cviMVs-PzwtbpZZL0SZMoRcggXdaCpFiVgIUWBjC2dU7qCpSEHtCKWsS92AcbbW1hTO6lpKVUin5uxi5-2H8D5STKvtVJnaFjsKY1wpqLQsQZhc_QA63W0-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3096280174</pqid></control><display><type>article</type><title>Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis</title><source>Springer Link</source><creator>Miró, Òscar ; Mojarro, Enrique Martín ; Huré, Gabrielle ; Llorens, Pere ; Gil, Víctor ; Alquézar-Arbé, Aitor ; Bibiano, Carlos ; González, Nayra Cabrera ; Massó, Marta ; Strebel, Ivo ; Espinosa, Begoña ; Masó, Silvia Mínguez ; Wussler, Desiree ; Shrestha, Samyut ; Lopez-Ayala, Pedro ; Jacob, Javier ; Millán, Javier ; Andueza, Juan Antonio ; Alonso, Héctor ; Pàmies, Silvia Larrondo ; Cerdà, Jaume Farré ; Martínez, Celia Planco ; Herrero, Pablo ; Frank Peacock, W ; Mueller, Christian</creator><creatorcontrib>Miró, Òscar ; Mojarro, Enrique Martín ; Huré, Gabrielle ; Llorens, Pere ; Gil, Víctor ; Alquézar-Arbé, Aitor ; Bibiano, Carlos ; González, Nayra Cabrera ; Massó, Marta ; Strebel, Ivo ; Espinosa, Begoña ; Masó, Silvia Mínguez ; Wussler, Desiree ; Shrestha, Samyut ; Lopez-Ayala, Pedro ; Jacob, Javier ; Millán, Javier ; Andueza, Juan Antonio ; Alonso, Héctor ; Pàmies, Silvia Larrondo ; Cerdà, Jaume Farré ; Martínez, Celia Planco ; Herrero, Pablo ; Frank Peacock, W ; Mueller, Christian</creatorcontrib><description>Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated with improved outcomes. We investigated factors related to digoxin initiation after an episode of AHF and whether patients receiving digoxin presented better short-term outcomes. We analyzed digoxin-naïve AHF patients from a Spanish and Swiss database, who were dichotomized into cohorts based on their receipt of digoxin treatment at discharge. The relationship between digoxin initiation and 23 additional patient covariates, including chronic treatment, was investigated, as well as its association with 90-day combined adverse events (defined as all-cause death or AHF hospitalization). Of 13,105 patients (10,600/2505 from the Spanish/Swiss cohorts, respectively), the median (interquartile range) age was 83 (74.87) years, and 51% were women. Of these, 484 (3.7%) received digoxin at discharge, which was associated with AF, female sex, left ventricular ejection fraction (LVEF) &lt; 50%, and coming from the Spanish cohort. Parameters inversely associated with receiving digoxin at discharge included some chronic treatments, diabetes mellitus (DM), and chronic kidney disease (CKD). Digoxin initiation was not association with 90-day adverse events, adjusted hazard ratio (aHR) = 0.939 (0.769-1.146), but there was an interaction for CKD, aHR = 1.390 (0.831-2.325) vs. 0.854 (0.682-1.183), p = 0.039, and for cohort pertinence, with higher risk in the Swiss cohort; aHR = 1.405 (0.827-2.386) vs. 0.862 (0.689-1.077), p = 0.046. Digoxin initiation after an AHF episode was more frequent in the Spanish cohort and was associated with certain patient characteristics (AF, female sex, reduced LVEF, no DM, no CKD), but had no effect on 90-day outcomes.Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated with improved outcomes. We investigated factors related to digoxin initiation after an episode of AHF and whether patients receiving digoxin presented better short-term outcomes. We analyzed digoxin-naïve AHF patients from a Spanish and Swiss database, who were dichotomized into cohorts based on their receipt of digoxin treatment at discharge. The relationship between digoxin initiation and 23 additional patient covariates, including chronic treatment, was investigated, as well as its association with 90-day combined adverse events (defined as all-cause death or AHF hospitalization). Of 13,105 patients (10,600/2505 from the Spanish/Swiss cohorts, respectively), the median (interquartile range) age was 83 (74.87) years, and 51% were women. Of these, 484 (3.7%) received digoxin at discharge, which was associated with AF, female sex, left ventricular ejection fraction (LVEF) &lt; 50%, and coming from the Spanish cohort. Parameters inversely associated with receiving digoxin at discharge included some chronic treatments, diabetes mellitus (DM), and chronic kidney disease (CKD). Digoxin initiation was not association with 90-day adverse events, adjusted hazard ratio (aHR) = 0.939 (0.769-1.146), but there was an interaction for CKD, aHR = 1.390 (0.831-2.325) vs. 0.854 (0.682-1.183), p = 0.039, and for cohort pertinence, with higher risk in the Swiss cohort; aHR = 1.405 (0.827-2.386) vs. 0.862 (0.689-1.077), p = 0.046. Digoxin initiation after an AHF episode was more frequent in the Spanish cohort and was associated with certain patient characteristics (AF, female sex, reduced LVEF, no DM, no CKD), but had no effect on 90-day outcomes.</description><identifier>ISSN: 1970-9366</identifier><identifier>EISSN: 1970-9366</identifier><identifier>DOI: 10.1007/s11739-024-03744-y</identifier><language>eng</language><ispartof>Internal and emergency medicine, 2024-08</ispartof><rights>2024. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Miró, Òscar</creatorcontrib><creatorcontrib>Mojarro, Enrique Martín</creatorcontrib><creatorcontrib>Huré, Gabrielle</creatorcontrib><creatorcontrib>Llorens, Pere</creatorcontrib><creatorcontrib>Gil, Víctor</creatorcontrib><creatorcontrib>Alquézar-Arbé, Aitor</creatorcontrib><creatorcontrib>Bibiano, Carlos</creatorcontrib><creatorcontrib>González, Nayra Cabrera</creatorcontrib><creatorcontrib>Massó, Marta</creatorcontrib><creatorcontrib>Strebel, Ivo</creatorcontrib><creatorcontrib>Espinosa, Begoña</creatorcontrib><creatorcontrib>Masó, Silvia Mínguez</creatorcontrib><creatorcontrib>Wussler, Desiree</creatorcontrib><creatorcontrib>Shrestha, Samyut</creatorcontrib><creatorcontrib>Lopez-Ayala, Pedro</creatorcontrib><creatorcontrib>Jacob, Javier</creatorcontrib><creatorcontrib>Millán, Javier</creatorcontrib><creatorcontrib>Andueza, Juan Antonio</creatorcontrib><creatorcontrib>Alonso, Héctor</creatorcontrib><creatorcontrib>Pàmies, Silvia Larrondo</creatorcontrib><creatorcontrib>Cerdà, Jaume Farré</creatorcontrib><creatorcontrib>Martínez, Celia Planco</creatorcontrib><creatorcontrib>Herrero, Pablo</creatorcontrib><creatorcontrib>Frank Peacock, W</creatorcontrib><creatorcontrib>Mueller, Christian</creatorcontrib><title>Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis</title><title>Internal and emergency medicine</title><description>Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated with improved outcomes. We investigated factors related to digoxin initiation after an episode of AHF and whether patients receiving digoxin presented better short-term outcomes. We analyzed digoxin-naïve AHF patients from a Spanish and Swiss database, who were dichotomized into cohorts based on their receipt of digoxin treatment at discharge. The relationship between digoxin initiation and 23 additional patient covariates, including chronic treatment, was investigated, as well as its association with 90-day combined adverse events (defined as all-cause death or AHF hospitalization). Of 13,105 patients (10,600/2505 from the Spanish/Swiss cohorts, respectively), the median (interquartile range) age was 83 (74.87) years, and 51% were women. Of these, 484 (3.7%) received digoxin at discharge, which was associated with AF, female sex, left ventricular ejection fraction (LVEF) &lt; 50%, and coming from the Spanish cohort. Parameters inversely associated with receiving digoxin at discharge included some chronic treatments, diabetes mellitus (DM), and chronic kidney disease (CKD). Digoxin initiation was not association with 90-day adverse events, adjusted hazard ratio (aHR) = 0.939 (0.769-1.146), but there was an interaction for CKD, aHR = 1.390 (0.831-2.325) vs. 0.854 (0.682-1.183), p = 0.039, and for cohort pertinence, with higher risk in the Swiss cohort; aHR = 1.405 (0.827-2.386) vs. 0.862 (0.689-1.077), p = 0.046. Digoxin initiation after an AHF episode was more frequent in the Spanish cohort and was associated with certain patient characteristics (AF, female sex, reduced LVEF, no DM, no CKD), but had no effect on 90-day outcomes.Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated with improved outcomes. We investigated factors related to digoxin initiation after an episode of AHF and whether patients receiving digoxin presented better short-term outcomes. We analyzed digoxin-naïve AHF patients from a Spanish and Swiss database, who were dichotomized into cohorts based on their receipt of digoxin treatment at discharge. The relationship between digoxin initiation and 23 additional patient covariates, including chronic treatment, was investigated, as well as its association with 90-day combined adverse events (defined as all-cause death or AHF hospitalization). Of 13,105 patients (10,600/2505 from the Spanish/Swiss cohorts, respectively), the median (interquartile range) age was 83 (74.87) years, and 51% were women. Of these, 484 (3.7%) received digoxin at discharge, which was associated with AF, female sex, left ventricular ejection fraction (LVEF) &lt; 50%, and coming from the Spanish cohort. Parameters inversely associated with receiving digoxin at discharge included some chronic treatments, diabetes mellitus (DM), and chronic kidney disease (CKD). Digoxin initiation was not association with 90-day adverse events, adjusted hazard ratio (aHR) = 0.939 (0.769-1.146), but there was an interaction for CKD, aHR = 1.390 (0.831-2.325) vs. 0.854 (0.682-1.183), p = 0.039, and for cohort pertinence, with higher risk in the Swiss cohort; aHR = 1.405 (0.827-2.386) vs. 0.862 (0.689-1.077), p = 0.046. Digoxin initiation after an AHF episode was more frequent in the Spanish cohort and was associated with certain patient characteristics (AF, female sex, reduced LVEF, no DM, no CKD), but had no effect on 90-day outcomes.</description><issn>1970-9366</issn><issn>1970-9366</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNjstOwzAQRS0EEqXwA6y8ZBMY24mdsEPlKVViA-tq4oxbozQOsSPgK_hlAu2C1T3SzJy5jJ0LuBQA5ioKYVSVgcwzUCbPs68DNhOVgaxSWh_-42N2EuMbQFFoYWbs-9avw6fvuO988ph86Di6RAPHCeyYiG8Ih8Qd-nYciFPvY2hoGjfcp8gxxmD3hx8-bXgfYsoaH-0GhzXxMCYbthSvf4W-m8zd3zK2fDu2yVvqdt-w_Yo-nrIjh22ks33O2ev93cviMVs-PzwtbpZZL0SZMoRcggXdaCpFiVgIUWBjC2dU7qCpSEHtCKWsS92AcbbW1hTO6lpKVUin5uxi5-2H8D5STKvtVJnaFjsKY1wpqLQsQZhc_QA63W0-</recordid><startdate>20240822</startdate><enddate>20240822</enddate><creator>Miró, Òscar</creator><creator>Mojarro, Enrique Martín</creator><creator>Huré, Gabrielle</creator><creator>Llorens, Pere</creator><creator>Gil, Víctor</creator><creator>Alquézar-Arbé, Aitor</creator><creator>Bibiano, Carlos</creator><creator>González, Nayra Cabrera</creator><creator>Massó, Marta</creator><creator>Strebel, Ivo</creator><creator>Espinosa, Begoña</creator><creator>Masó, Silvia Mínguez</creator><creator>Wussler, Desiree</creator><creator>Shrestha, Samyut</creator><creator>Lopez-Ayala, Pedro</creator><creator>Jacob, Javier</creator><creator>Millán, Javier</creator><creator>Andueza, Juan Antonio</creator><creator>Alonso, Héctor</creator><creator>Pàmies, Silvia Larrondo</creator><creator>Cerdà, Jaume Farré</creator><creator>Martínez, Celia Planco</creator><creator>Herrero, Pablo</creator><creator>Frank Peacock, W</creator><creator>Mueller, Christian</creator><scope>7X8</scope></search><sort><creationdate>20240822</creationdate><title>Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis</title><author>Miró, Òscar ; Mojarro, Enrique Martín ; Huré, Gabrielle ; Llorens, Pere ; Gil, Víctor ; Alquézar-Arbé, Aitor ; Bibiano, Carlos ; González, Nayra Cabrera ; Massó, Marta ; Strebel, Ivo ; Espinosa, Begoña ; Masó, Silvia Mínguez ; Wussler, Desiree ; Shrestha, Samyut ; Lopez-Ayala, Pedro ; Jacob, Javier ; Millán, Javier ; Andueza, Juan Antonio ; Alonso, Héctor ; Pàmies, Silvia Larrondo ; Cerdà, Jaume Farré ; Martínez, Celia Planco ; Herrero, Pablo ; Frank Peacock, W ; Mueller, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p118t-a0420c06d6e818aa5115adc5f734f0d9e30bfea22b86d07fcb6c75fc6b22352f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miró, Òscar</creatorcontrib><creatorcontrib>Mojarro, Enrique Martín</creatorcontrib><creatorcontrib>Huré, Gabrielle</creatorcontrib><creatorcontrib>Llorens, Pere</creatorcontrib><creatorcontrib>Gil, Víctor</creatorcontrib><creatorcontrib>Alquézar-Arbé, Aitor</creatorcontrib><creatorcontrib>Bibiano, Carlos</creatorcontrib><creatorcontrib>González, Nayra Cabrera</creatorcontrib><creatorcontrib>Massó, Marta</creatorcontrib><creatorcontrib>Strebel, Ivo</creatorcontrib><creatorcontrib>Espinosa, Begoña</creatorcontrib><creatorcontrib>Masó, Silvia Mínguez</creatorcontrib><creatorcontrib>Wussler, Desiree</creatorcontrib><creatorcontrib>Shrestha, Samyut</creatorcontrib><creatorcontrib>Lopez-Ayala, Pedro</creatorcontrib><creatorcontrib>Jacob, Javier</creatorcontrib><creatorcontrib>Millán, Javier</creatorcontrib><creatorcontrib>Andueza, Juan Antonio</creatorcontrib><creatorcontrib>Alonso, Héctor</creatorcontrib><creatorcontrib>Pàmies, Silvia Larrondo</creatorcontrib><creatorcontrib>Cerdà, Jaume Farré</creatorcontrib><creatorcontrib>Martínez, Celia Planco</creatorcontrib><creatorcontrib>Herrero, Pablo</creatorcontrib><creatorcontrib>Frank Peacock, W</creatorcontrib><creatorcontrib>Mueller, Christian</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Internal and emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miró, Òscar</au><au>Mojarro, Enrique Martín</au><au>Huré, Gabrielle</au><au>Llorens, Pere</au><au>Gil, Víctor</au><au>Alquézar-Arbé, Aitor</au><au>Bibiano, Carlos</au><au>González, Nayra Cabrera</au><au>Massó, Marta</au><au>Strebel, Ivo</au><au>Espinosa, Begoña</au><au>Masó, Silvia Mínguez</au><au>Wussler, Desiree</au><au>Shrestha, Samyut</au><au>Lopez-Ayala, Pedro</au><au>Jacob, Javier</au><au>Millán, Javier</au><au>Andueza, Juan Antonio</au><au>Alonso, Héctor</au><au>Pàmies, Silvia Larrondo</au><au>Cerdà, Jaume Farré</au><au>Martínez, Celia Planco</au><au>Herrero, Pablo</au><au>Frank Peacock, W</au><au>Mueller, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis</atitle><jtitle>Internal and emergency medicine</jtitle><date>2024-08-22</date><risdate>2024</risdate><issn>1970-9366</issn><eissn>1970-9366</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated with improved outcomes. We investigated factors related to digoxin initiation after an episode of AHF and whether patients receiving digoxin presented better short-term outcomes. We analyzed digoxin-naïve AHF patients from a Spanish and Swiss database, who were dichotomized into cohorts based on their receipt of digoxin treatment at discharge. The relationship between digoxin initiation and 23 additional patient covariates, including chronic treatment, was investigated, as well as its association with 90-day combined adverse events (defined as all-cause death or AHF hospitalization). Of 13,105 patients (10,600/2505 from the Spanish/Swiss cohorts, respectively), the median (interquartile range) age was 83 (74.87) years, and 51% were women. Of these, 484 (3.7%) received digoxin at discharge, which was associated with AF, female sex, left ventricular ejection fraction (LVEF) &lt; 50%, and coming from the Spanish cohort. Parameters inversely associated with receiving digoxin at discharge included some chronic treatments, diabetes mellitus (DM), and chronic kidney disease (CKD). Digoxin initiation was not association with 90-day adverse events, adjusted hazard ratio (aHR) = 0.939 (0.769-1.146), but there was an interaction for CKD, aHR = 1.390 (0.831-2.325) vs. 0.854 (0.682-1.183), p = 0.039, and for cohort pertinence, with higher risk in the Swiss cohort; aHR = 1.405 (0.827-2.386) vs. 0.862 (0.689-1.077), p = 0.046. Digoxin initiation after an AHF episode was more frequent in the Spanish cohort and was associated with certain patient characteristics (AF, female sex, reduced LVEF, no DM, no CKD), but had no effect on 90-day outcomes.Digoxin is commonly used to treat acute heart failure (AHF), especially in patients with concurrent atrial fibrillation (AF). Nonetheless, there is little consensus about in which patients digoxin should be given, the proper time for digoxin initiation, and whether digoxin initiation is associated with improved outcomes. We investigated factors related to digoxin initiation after an episode of AHF and whether patients receiving digoxin presented better short-term outcomes. We analyzed digoxin-naïve AHF patients from a Spanish and Swiss database, who were dichotomized into cohorts based on their receipt of digoxin treatment at discharge. The relationship between digoxin initiation and 23 additional patient covariates, including chronic treatment, was investigated, as well as its association with 90-day combined adverse events (defined as all-cause death or AHF hospitalization). Of 13,105 patients (10,600/2505 from the Spanish/Swiss cohorts, respectively), the median (interquartile range) age was 83 (74.87) years, and 51% were women. Of these, 484 (3.7%) received digoxin at discharge, which was associated with AF, female sex, left ventricular ejection fraction (LVEF) &lt; 50%, and coming from the Spanish cohort. Parameters inversely associated with receiving digoxin at discharge included some chronic treatments, diabetes mellitus (DM), and chronic kidney disease (CKD). Digoxin initiation was not association with 90-day adverse events, adjusted hazard ratio (aHR) = 0.939 (0.769-1.146), but there was an interaction for CKD, aHR = 1.390 (0.831-2.325) vs. 0.854 (0.682-1.183), p = 0.039, and for cohort pertinence, with higher risk in the Swiss cohort; aHR = 1.405 (0.827-2.386) vs. 0.862 (0.689-1.077), p = 0.046. Digoxin initiation after an AHF episode was more frequent in the Spanish cohort and was associated with certain patient characteristics (AF, female sex, reduced LVEF, no DM, no CKD), but had no effect on 90-day outcomes.</abstract><doi>10.1007/s11739-024-03744-y</doi></addata></record>
fulltext fulltext
identifier ISSN: 1970-9366
ispartof Internal and emergency medicine, 2024-08
issn 1970-9366
1970-9366
language eng
recordid cdi_proquest_miscellaneous_3096280174
source Springer Link
title Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T12%3A42%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Digoxin%20initiation%20after%20an%20acute%20heart%20failure%20episode%20and%20its%20association%20with%20post-discharge%20outcomes:%20an%20international%20multicenter%20analysis&rft.jtitle=Internal%20and%20emergency%20medicine&rft.au=Mir%C3%B3,%20%C3%92scar&rft.date=2024-08-22&rft.issn=1970-9366&rft.eissn=1970-9366&rft_id=info:doi/10.1007/s11739-024-03744-y&rft_dat=%3Cproquest%3E3096280174%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p118t-a0420c06d6e818aa5115adc5f734f0d9e30bfea22b86d07fcb6c75fc6b22352f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3096280174&rft_id=info:pmid/&rfr_iscdi=true